Navigation Links
Clinical DataBase

ProductsClinical DataBase
Company Bio-Optics
Item Clinical DataBase
Features The database is in Paradox for Windows format and can be imported into Borland Paradox, Microsoft Access, Microsoft FoxPro, Oracle or most other database packages and expanded as desired.
Description ClinicDB is a multi-page database similar to EyebankDB but that maintains a database of patient information, laboratory and specular microscopy results, adverse reactions, etc. and can print adverse reaction reports, letters and invoices that are necessary in the operation of an eye clinic.
Info Bio-Optics
Customer Service: (503) 493-8000
Web site: http://www.bio-optics.com/

Related medicine products :

1. Freedom EVO Clinical
2. OLA2500 Clinical Lab Automation System
3. OLA4000 Clinical Lab Automation System
4. Aeroset Clinical Chemistry System
5. Express Plus Clinical Chemistry Analyzer
6. i-STAT Portable Clinical Analyzer
7. HAI CL-1000xyzClinical Specular Microscope
8. UniCel DxC 600 Synchron Clinical System
9. Clinical Information System
10. The Clinical Reference Laboratories at National Jewish Medical and Research Center
11. Dermatology, Allergy and Clinical Immunology (DACI) Reference Laboratory
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches.
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches.
Medicine Products:
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...nce of Oral and Overall Health, HARRISBURG, Pa., ...ted,Concordia Dental is celebrating National Smile...a and the British Dental Health Foundation to,prom...h. Beginning May 18,this year,s event is launchin...it the largest independent international dental he...
(Date:5/16/2008)...nefit from calcitriol, an oral form , , ...d vitamin D may cut the risk of death for people w...bout one quarter, a new study suggests. , Duri...hose being treated with calcitriol, an oral form o...eath lowered by 26 percent when compared with thos...
(Date:5/16/2008)...niors and People With,Disabilities, OAKLAND, Cali...,homecare workers across the state are outraged by...rs of service, wages and benefits,which would for...d the,people they serve deeper into poverty. They ...nd people with disabilities from Schwarzenegger,s,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
... found a herb used in traditional Indian medicine ...nsulin levels // in a manner similar to prescripti...a herb called salacia oblonga, which is native to ...oblonga binds to intestinal enzymes that break dow...
...reveals that a compound in carrots may reduce the ...ve found // that falcarinol, a natural pesticide f...duces the risk of developing cancer. Falcarinol pr...h as licorice rot, which causes black spots on the...
...y that looked at how in utero exposures affect the... say, larger babies // have a higher risk of devel...ay associations between larger birth weight and in... proposed, but there have been few studies to exam...
...disease are more likely to suffer from atheroscler...d to heart attack // or stroke shows latest resear...ria levels in the mouths of 657 people who had no ...hickness of the subjects' carotid artery, used to ...
Other Medicine News:
(Date:5/15/2008)... - Unprecedented amount of research reflects dept...s worldwide to develop new treatments for ... session to highlight impact of Zometa(R), the lea...ts with early-stage breast cancer, - Four oral se...ntinuous, inhibitor of mTOR, including first resul...
(Date:5/15/2008)...d pressure reductions demonstrated in Blacks, Hisp...es and Obese Individuals, PARSIPPANY, N.J., May 1...today that data presented at the American Society ...Meeting (ASH 2008) in New,Orleans demonstrated tha...ne and olmesartan medoxomil) safely and effectivel...
(Date:5/15/2008)...xcellent results obtained with a newly cleared dev...plaques of interest that are associated with ...BURLINGTON, Mass., May 15 /- InfraReD...t Hospital in Royal Oak, Mich., have,successfully ... patient,undergoing a cardiac catheterization. Thi...
(Date:5/15/2008)...APPENZELL, Switzerland, May 15 /- Erg... Food and Drug Administration (FDA) has,granted or...nt of pulmonary,arterial hypertension (PAH). Tergu...otal Phase II trial in Europe., "The FDA,s grant ...courages and strengthens our development program b...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2James T Glover Appointed to Board of Directors of Varian Inc 5197 1James T Glover Appointed to Board of Directors of Varian Inc 5197 2USC receives nearly 2427 million in funding for new stem cell research facility 18716 1USC receives nearly 2427 million in funding for new stem cell research facility 18716 2IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 1IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 2The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 1The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 2The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 3The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 4The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 5The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 6The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 7The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 8The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 9The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 10
...orted by the,National Institutes of Healths Nati...and Skin Diseases (NIAMS) shows that the,anticon... certain,types of seizures, can be an effective ...ated with the common, often hard-to-treat,chroni...onsored, randomized, double-blind clinical trial,...
...via COMTEX News,Network) -- Myriad Genetics, Inc. ...ww.myriad.com/">www.myriad.com ),announced today t...taggered Start" and a "Randomized Withdrawal" clin...d Start" clinical trial,design at the Alzheimer,s ..., 2007, in Washington, D.C. The analysis demonstra...
Other Medicine Technology:Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5